Advance Search
XU Dongmei, GONG Zheng, DING Zhaosheng. Valsartan combined with amlodipine versus valsartan combined with hydrochlorothiazide in treatment of patients with hypertension[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 58-61. DOI: 10.7619/jcmp.20220186
Citation: XU Dongmei, GONG Zheng, DING Zhaosheng. Valsartan combined with amlodipine versus valsartan combined with hydrochlorothiazide in treatment of patients with hypertension[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 58-61. DOI: 10.7619/jcmp.20220186
shu

Valsartan combined with amlodipine versus valsartan combined with hydrochlorothiazide in treatment of patients with hypertension

  • Jiangsu Provincial Rongjun Hospital, Wuxi, Jiangsu, 214035

More Information
  • Received Date: January 13, 2022
  • Available Online: May 24, 2022
    Graphical Abstract
    • Abstract
  • Objective 

    To compare the efficacy and safety of valsartan combined with amlodipine and valsartan combined with hydrochlorothiazide in the treatment of patients with hypertension.

    Methods 

    A total of 120 eldely patients with hypertension were randomly divided into observation group and control group.The observation group was treated with valsartan and amlodipine, while the control group was treated with valsartan and hydrochlorothiazide.The changes of 24 h blood pressure, nitric oxide (NO) and endothelin (ET) before and after treatment were compared between the two groups, and the condition of blood pressure reaching standard and adverse reactions of drugs were observed in both groups.

    Results 

    There were no significant differences in 24 h systolic blood pressure and diastolic blood pressure before treatment between the two groups (P>0.05);the 24 h systolic blood pressure after treatment in the observation group was (126.5±8.9) mmHg, which was significantly lower than (134.8±9.1) mmHg in the control group (P < 0.05).After treatment, the rates of blood pressure reaching standard in the observation group and the control group were 95.0% and 93.0% respectively.After treatment, the NO levels in the observation group and the control group were (69.6±18.7) and (65.4±15.2)μmol/L respectively, which were significantly higher than (27.5±13.5) and (27.6±13.4)μmol/L before treatment in both groups (P < 0.05);the ET levels were (33.2±4.5) and (37.1±5.4) ng/L in the observation group and the control group, which were significantly lower than (45.5±8.2) and (45.8±8.4) ng/L before treatment in both groups (P < 0.05);serum NO level after treatment in the observation group was significantly higher than that in the control group, and ET was significantly lower than that in the control group (P < 0.05).After treatment, the total incidence rate of adverse reactions in the observation group was 8.3%, which was significantly lower than 16.7% in the control group (P < 0.05).

    Conclusion 

    For elderly patients with hypertension, valsartan combined with amlodipine can more effectively control systolic blood pressure, increase serum NO level, reduce ET level and protect vascular endothelial function.

    • FullText(HTML)
    • References (22)
  • [1]
    徐春红, 刘玉爽, 焦春颜. 强化健康管理对高血压患者血压及生存质量的影响[J]. 实用临床医药杂志, 2020, 24(18): 68-70. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202018021.htm
    [2]
    刘刚, 王艳. 缬沙坦联合苯磺酸氨氯地平与氢氯噻嗪对高血压伴阵发性房颤患者心功能及血清炎性因子水平的影响[J]. 医学临床研究, 2018, 35(10): 2026-2028. doi: 10.3969/j.issn.1671-7171.2018.10.056
    [3]
    严华, 郭芳云. 缬沙坦联合氨氯地平治疗老年高血压的临床效果[J]. 临床医学研究与实践, 2021, 6(4): 70-72. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202104025.htm
    [4]
    王雪燕, 张庆考. 氨氯地平单药与氨氯地平联合缬沙坦治疗高危高血压患者的疗效比较[J]. 实用临床医药杂志, 2016, 20(23): 122-124. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201623042.htm
    [5]
    WANG X O, TIAN W. Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension[J]. Medicine, 2019, 98(26): e16264. doi: 10.1097/MD.0000000000016264
    [6]
    KHAN K M, IQTADAR S, NASIR M, et al. Amlodipine/valsartan (avsar): efficacy in hypertensive patients. A real world observational study (ALERT)[J]. Cureus, 2020, 12(5): e8174.
    [7]
    JIN X, KIM M H, HAN K H, et al. Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia[J]. J Clin Hypertens (Greenwich), 2020, 22(10): 1835-1845. doi: 10.1111/jch.13893
    [8]
    《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1): 1-44. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201901003.htm
    [9]
    DELAVAR F, PASHAEYPOOR S, NEGARANDEH R. The effects of self-management education tailored to health literacy on medication adherence and blood pressure control among elderly people with primary hypertension: a randomized controlled trial[J]. Patient Educ Couns, 2020, 103(2): 336-342. doi: 10.1016/j.pec.2019.08.028
    [10]
    IDDRISU M A, SENADJKI A, MOHD S, et al. The impact of HPB on elderly diseases (diabetes mellitus, hypertension, hypercholesterolemia, minor stroke, kidney failure and heart problem): a logistic analysis[J]. Ageing Int, 2020, 45(2): 149-180.
    [11]
    李稳, 李刚. 《老年高血压的诊断与治疗中国专家共识(2017版)》要点介绍[J]. 中华高血压杂志, 2018, 26(10): 986-989. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201810027.htm
    [12]
    李静, 范利, 华琦, 等. 中国老年高血压管理指南2019[J]. 中华高血压杂志, 2019, 27(2): 111-135. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201902010.htm
    [13]
    陈鲁原, 卢新政. 单片复方制剂降压治疗中国专家共识[J]. 中华高血压杂志, 2019, 27(4): 310-317. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904006.htm
    [14]
    李占华, 李孛. 苯磺酸氨氯地平片联合缬沙坦氢氯噻嗪片治疗中青年2级高血压临床观察[J]. 空军医学杂志, 2020, 36(3): 248-250. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZY202003019.htm
    [15]
    赵建霞. 苯磺酸左旋氨氯地平、缬沙坦联合吲达帕胺治疗顽固性高血压的临床效果分析[J]. 海峡药学, 2019, 31(11): 168-169. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIX201911067.htm
    [16]
    钱晋, 谈世进. 缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性的影响[J]. 老年医学与保健, 2015, 21(2): 112-114, 129. https://www.cnki.com.cn/Article/CJFDTOTAL-LYBJ201502015.htm
    [17]
    夏碧荣, 公振宇. 缬沙坦联合氨氯地平与缬沙坦联合氢氯噻嗪治疗老年高血压患者的效果研究[J]. 中国社区医师, 2021, 37(9): 61-62. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS202109030.htm
    [18]
    高强. 缬沙坦分别联合氨氯地平、氢氯噻嗪治疗老年性高血压效果比较[J]. 临床合理用药杂志, 2020, 13(2): 49-50. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202002026.htm
    [19]
    姚娬斌. 缬沙坦氨氯地平用于维持性血液透析伴高血压患者血压调控的临床效果[J]. 临床合理用药杂志, 2021, 14(5): 63-65. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202105025.htm
    [20]
    杨静, 李钰兰. 缬沙坦氨氯地平片联合阿托伐他汀钙片治疗高血压伴高血脂的临床效果及其对血管与心肌的保护作用[J]. 中国慢性病预防与控制, 2017, 25(3): 224-226. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB201703019.htm
    [21]
    李劲鸿, 王红. 缬沙坦氨氯地平片联合α-硫辛酸治疗老年2型糖尿病肾病合并高血压的效果及安全性[J]. 昆明医科大学学报, 2021, 42(4): 53-56. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202104010.htm
    [22]
    魏永平, 曾翠连, 叶定村, 等. 缬沙坦与苯磺酸氨氯地平治疗高血压的总有效率及不良反应发生情况分析[J]. 河北医药, 2017, 39(7): 1023-1025. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201707018.htm
    • Related Articles

  • Related Articles

    [1]XUE Xiaodan, ZHOU Yanfei, YAN Huijuan. Effect of vaginal sacrospinous ligament suspension with uterus preservation in treatment of patients with moderate to severe pelvic organ prolapse[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 87-91. DOI: 10.7619/jcmp.20242930
    [2]XU Chunhuan, WU Jia, YANG Jinying, YUE Yanling. Efficacy of U-shaped sacrospinous ligament fixation in the treatment of pelvic organ prolapse[J]. Journal of Clinical Medicine in Practice, 2023, 27(16): 79-83. DOI: 10.7619/jcmp.20231002
    [3]DONG Chunlin, SONG Jing, WANG Yuan, YU Jinjin. Effect of improved bilateral sacrospinous ligament fixation in treatment of pelvic organ prolapse[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 103-105. DOI: 10.7619/jcmp.202024031
    [4]ZHENG Yafeng, JIANG Yunfen, CHEN Jiming, QIN Zhenyue, LIU Junling, LU Jia, XIAO Huichao, LU Bingying, SHI Ruxia. Clinical analysis of sacrospinous ligament fixation with conventional surgical instrument under direct vision in treatment of pelvic organ prolapse[J]. Journal of Clinical Medicine in Practice, 2020, 24(9): 77-79. DOI: 10.7619/jcmp.202009022
    [5]YANG Yaqi. Perioperative nursing of uterine prolapse treated by colpohysterectomy and anterior and posterior wall colporrhaphy in senile patients[J]. Journal of Clinical Medicine in Practice, 2016, (18): 134-136. DOI: 10.7619/jcmp.201618043
    [6]ZHOU Liulin, YANG Jishi, YIN Huiqin, HAO Zhenfeng, QIAN Lihua, HONG Qiuhui. Effect comparison between anterior vaginal wall bridge repairment surgery and anterior pelvic floor reconstruction surgery in the treatment of vaginal anterior wall prolapse[J]. Journal of Clinical Medicine in Practice, 2014, (19): 77-80. DOI: 10.7619/jcmp.201419023
    [7]ZHANG Yan. Health education guidance and nursing of patients with uterine prolapse[J]. Journal of Clinical Medicine in Practice, 2014, (12): 152-153,159. DOI: 10.7619/jcmp.201412055
    [8]XU Yan, JU Xiaomei, HE Chenyun, HE Aiqin. Nursing for pelvic organ prolapse patients with cervicovaginal abdominal wall fascia suspension[J]. Journal of Clinical Medicine in Practice, 2013, (20): 88-90. DOI: 10.7619/jcmp.201320030
    [9]CHEN Wanjun, LIU Yanxia, CHEN Huan. Perioperative nursing for severe prolapse of pelvic organs patients with combination treatment of transvaginal Prosima mesh and high uteroligment susppention[J]. Journal of Clinical Medicine in Practice, 2013, (10): 91-94. DOI: 10.7619/jcmp.201310034
    [10]WENG Xiao-ping. Bridge type vaginal wall of repair in the treatment of pelvicorgan prolapse[J]. Journal of Clinical Medicine in Practice, 2012, (15): 82-83.

  • Cited by

    Periodical cited type(5)

    1. 黄芳，张纯，陈宝莹，卢肖霞，梁曼谊，罗允内. 穴位贴敷治疗咳嗽变异性哮喘的临床研究. 中国医药科学. 2022(04): 71-73 .
    2. 严瑾，王继鹏. 肺泡气一氧化氮对咳嗽变异性哮喘ICS+LABA治疗反应的意义. 中华肺部疾病杂志(电子版). 2022(05): 673-675 .
    3. 钱星佳，吕红. 从“风”论治咳嗽变异性哮喘的研究概况. 中医临床研究. 2022(21): 48-51 .
    4. 肖超扬. 一氧化氮测定仪诊断小儿咳嗽变异性哮喘的价值体会. 中国医疗器械信息. 2020(20): 68-69 .
    5. 车玲艳，刘建红，樊延平. 苏黄止咳胶囊联合沙美特罗替卡松对咳嗽变异性哮喘患者疗效及对肺功能指标的影响. 山西医药杂志. 2020(23): 3303-3305 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML
    Article views (236) PDF downloads (21) Cited by(9)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return